H2020-NMBP-TR-IND-2020-twostage
Next generation organ-on-chip (RIA-LS)

Tumor-LN-oC

Tumor and Lymph Node on Chip for cancer studies

Starting date of the project: 01/05/2021
Duration: 48 months

= Deliverable D17.1 =

Dissemination and communication activities - Period A

Due date of deliverable: 30/04/2023
Actual submission date: 30/04/2023

Responsible WP: Kristin Aldag, AMI
Responsible TL: Kristin Aldag, AMI
Revision: V1.0

Dissemination level		
PU	Public	X
PP	Restricted to other programme participants (including the Commission Services)	
RE	Restricted to a group specified by the consortium (including the Commission Services)	
CO	Confidential, only for members of the consortium (including the Commission Services)	

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953234.

AUTHOR

Author	Institution	Contact (e-mail, phone)
Kristin Aldag	AMI	aldag@amires.eu
All partners contributing		

DOCUMENT HISTORY

Document version	Date	Change
0.1	15.04.2023	Pre-final draft sent to consortium
0.2	20.04.2023	Final version sent to consortium
1.0	28.04.2023	Final version

VALIDATION

Reviewers	Validation date	Name
Work Package Leader	28.04.2023	Kristin Aldag, AMI
Project Manager	28.04.2023	Kristin Aldag, AMI
Coordinator	20.04.2023	Ioanna Zergioti, ICCS

DOCUMENT DATA

Keywords	Dissemination, Communication
Point of Contact	Name: Kristin Aldag Partner: AMI Address: Na Okraji 335/42, 162 00 Praha 6 Phone: +420 603 334 830 E-mail: aldag@amires.eu
Delivery date	30.04.2023

DISTRIBUTION LIST

Date	Issue	Recipients
19.04.2023	V0.1	Partners via email
30.04.2023	V1.0	Partners via OwnCloud, Commission via portal

DISCLAIMER

Any dissemination of results reflects only the authors' view and the European Commission Horizon 2020 is not responsible for any use that may be made of the information Deliverable D17.1 contains.

Executive Summary

This Deliverable reports on T17.1, "Implementation of high impact dissemination and communication activities – Period A". The task involved the design and production of the Tumor-LN-oC promotional materials, representation on the project website and through social media pages as well as the Tumor-LN-oC presence in conferences and other event, the dissemination of results in scientific/ technical journals, magazines and blogs. This document is a working document outlining the dissemination activities for the project's first period (M1-M24), the task will be seamlessly continued in T18.1 (M24 – M48).

Table of Contents

Table of figures

List of tables

1. Introduction

This Deliverable reports on T17.1, "Implementation of high impact dissemination and communication activities – Period A. Through this Task, the consortium, led by partner AMIRES, has implemented the communication and dissemination strategy and associated activities between M7-M24. The Task involved the design and production of the Tumor-LN-oC promotional, written and audio-visual digital materials (brochures, leaflets, newsletters and videos), as well as the coordination of Tumor-LN-oC presence in dissemination fora, such as conferences and events. Dissemination of results also included the publication of articles in scientific/ technical journals, magazines and blogs which, due to the nature of the project and subject matter, has been limited during the first half of the project. Through the task, Tumor-LN-oC was be represented through social media pages (i.e. LinkedIn) for easier access to larger audiences and industrial end users. At the same time, these bi-directional communication platforms are excellent means to receive feedback from the users' community, citizens, and Tumor-LN-oC -related organisations. Collaboration was also sought between the other active H2020 projects and Tumor- LN-oC will get in contact with other coordinators to exchange relevant project related information and invite each other to specific events.

2. Report on dissemination activities

2.1. Role of Dissemination manager

While all project partners are committed to communicate and disseminate project results, the dissemination manager role was created in order to ensure the dissemination obligations are met and the project generates the greatest possible reach and engages with stakeholders. The dissemination manager role is held by Kristin Aldag (AMIRES). Main roles and responsibilities of the dissemination manager include:

- Provision of printed or digital dissemination material to partners according to project visual identity
- Regular update posts and general maintenance of project website and social media channels
- Coordination, monitoring and reporting of consortium dissemination activities, such as event/conference participation and scientific publications
- Initial reaction to any external enquiries, e.g. via the contact form on the website, in close cooperation with the coordinator
- Ensuring flow of information between project partners
- Design and distribution of internal templates (e.g. presentations, deliverables, reports)
- Support to partners in all matters related to dissemination (e.g. event organisation or participation, website & social media, open access)
- Curating the Tumor-LN-oC Zenodo community

2.2. Tumor-LN-oC Dissemination materials

A core element of task 17.1 is the design and production of the Tumor-LN-oC promotional, written and audio-visual digital materials (brochures, leaflets, newsletters and videos). As already presented in the M18 report, Tumor-LN-oC partners have at their disposal a range of project dissemination materials (see Table 1).

Further material, e.g. posters, videos and press releases will be prepared and published once more project results are ready to be presented to the public and intellectual property considerations are advanced. All public materials can be downloaded from the project website (see Figure 1).

Table 1. Tumor-LN-oC Dissemination materials

Type	Status	Link
Logo	Summer 2021, no updates necessary	https://tumor-ln-oc.eu/wp-content/uploads/2021/08/TUMOR_logo.svg
Initial press release	02.09.2021, no updates necessary	https://tumor-ln-oc.eu/wp-content/uploads/2021/09/Tumor-LN-oC-press-release_KA.pdf
Factsheet	30.09.2021, no updates necessary	https://tumor-ln-oc.eu/wp-content/uploads/2021/09/Tumor-LN-oC_bullet-point-summary.pdf
Leaflet	01.05.2022, no updates necessary	https://tumor-ln-oc.eu/wp-content/uploads/2022/05/TUMOR_leaflet_1.0.pdf
Presentation	15.07.2022, pending update on project progress	https://tumor-ln-oc.eu/wp-content/uploads/2023/04/Tumor-LN-oC_general-presentation_v1.0.pdf
Roll-Up	17.04.2023	https://owncloud.amires.eu/index.php/s/hQfWVGFnLE2KSAp



Figure 1: Tumor-LN-oC Dissemination materials available for download on the project website



Figure 2: Project leaflet



Figure 3: Project presentation

Figure 4: Tumor-LN-oC Roll-Up Design (pending printing)

2.3. Templates

In addition to external visual materials, project partners have access to internal templates for presentations, deliverables, reports and any other necessary documents in the Tumor-LN-oC design. They are available anytime on the OwnCloud Filesharing platform. In addition, updated templates are shared prior to any project meeting.



Figure 5: Internal PowerPoint Template, e.g. for project meetings

2.4. Project Website

2.4.1. Overview

The Tumor-LN-oC website is available at https://tumor-ln-oc.eu/

The website provides interested public with all basic information about the project, such as the objectives, impact and results, as well as the project consortium. The website is regularly updated with any news (see Figure 8). In addition, all dissemination materials, public deliverables and scientific publications are available for download (see Figure 1). The website is hosted on the WordPress platform and easily updated and maintained by the dissemination manager. The website also links to the Twitter and LinkedIn Page and offers a contact form which is redirected to the dissemination manager who forwards any relevant inquiries to the coordinator.



Figure 6: Tumor-LN-oC Website



Figure 7: "About" page

Figure 8: News and events section on the website

2.4.2. Website analytics

Google Analytics tools provides insight on relevant data, e.g. how many times the website has been visited and where users are located. Overall, since the beginning for the project, over 850 users have visited the website and the pages have been viewed a total of 2530 times. On average, users visit 2.12 pages per session and spend 1:35 minutes on a page (see Table 2). During the most recent M19-M24 period, the traffic has been rather low (see Figure 9,

Table 2), which will be attempted to be increased in coming months by more active posting and sharing.



Figure 9: Tumor-LN-oC Website statistics 01.11.2021 - 17.04.2023 (M6-M24)

Table 2: Website analytics – M1-M24 vs. M19-M24 (via Google Analytics)

Category	M1-M24 01.05.2021 – 17.04.2023	M19-M24 01.10.2022 – 17.04.2023
Users	850	83
Page views	2530 (2096 unique)	392 (320 unique)
Sessions	1194	152
Pages per session	2.12	2.58
Sessions per user	1.4	2.83
Average time on page	1:35 min	1:29 min
Average session duration	1:47 min	2:22 min
New visitor vs returning visitor	850 new (88.8%) 107 returning (11.2%)	82 new (75.9%) 26 returning (24.1%)

Nevertheless, the global reach is quite good with over 150 users visiting the site from the US and even 27 users from China (see Figure 10Figure 11). Countries in which Tumor-LN-oC partners are locates are most represented.

Not surprisingly, the homepage is the most visited page, followed by the consortium page, “about” page, news and events page, dissemination material page and contact page (see).

	Country	Users	% Users
1.	United States	159	18.30%
2.	Netherlands	130	14.96%
3.	Finland	112	12.89%
4.	Greece	83	9.55%
5.	France	52	5.98%
6.	Austria	50	5.75%
7.	Czechia	45	5.18%
8.	United Kingdom	40	4.60%
9.	China	27	3.11%
10.	Germany	25	2.88%

Figure 10: Location of website users 01.05.2021 - 17.04.2023 (M1-M24)

	Page	Page Views	% Page Views
1.	/	1,058	41.82%
2.	/project-team/	425	16.80%
3.	/about/	315	12.45%
4.	/news-events/	202	7.98%
5.	/dissemination-materials/	164	6.48%
6.	/contacts/	94	3.72%
7.	/tumor-ln-oc-project-has-kicked-off/	58	2.29%
8.	/questionnaire-for-end-users/	45	1.78%
9.	/tumor-ln-ocs-first-press-release/	42	1.66%
10.	/6-months-completed/	29	1.15%

Figure 11: Top pages viewed 01.05.2021 - 17.04.2023 (M1-M24)



Figure 12: Acquisition of users, 01.05.2021 - 17.04.2023 (M1-M24)

When it comes to acquisition of users to the Tumor-LN-oC website, or in other words ways people find the site, following results were achieved during M1-M24:

- 584 users visited the website directly, such as typing the website's URL directly into their browser
- 166 users came from organic search (unpaid listings on Google and other search engine results pages
- 73 users came via a referral - Traffic from links to Tumor-LN-oC website on other websites
- 67 users came from social media platforms, which includes LinkedIn and Twitter



Figure 13: New vs. returning users 01.05.2021 - 17.04.2023 (M1-M24)

The vast majority of website users are new visitors, meaning many people only visit once and don't come back to check for any updates. Ways to increase user retention will be explored and partners will be regularly reminded to share project news on their own channels in order to drive more traffic to the Tumor-LN-oC website.

3. Social media

Tumor-LN-oC representation through social media pages (i.e. LinkedIn, Twitter) is a great way to allow for easier communication with to larger audiences, the general public and industrial end users. At the same time, these bi-directional communication platforms are an excellent means to receive feedback from the users' community, citizens and stay up to date on Tumor-LN-oC -related undertakings. Short news stories about the Tumor-LN-oC project and its development are prepared and shared on the especially during events, conferences, and symposiums.

Dedicated pages were created for the Tumor-LN-oC project on LinkedIn and Twitter, which are considered the best way to reach and engage with the identified target audiences (scientific community, industry stakeholders, policy makers). In addition, partners are encouraged to share and post on their own channels about the project.

3.1.1. Twitter

The Tumor-LN-oC Twitter account is used to share any news and updated, real-time information about the project. Dissemination manager from AMIRES is account owner and responsible for regular post updates. All partners are encouraged to share any news and project results to be posted and regularly reminded of this possibility.

However, after ca. 1.5 years and over 25 posts, the Tumor-LN-oC twitter page has only 29 followers. In addition, as shown in Table 3, the reach and engagement with posts is rather low, so while the page will continue to be regularly updated and outreach will be attempted to be improved, other channels such as LinkedIn, where project partners are more active and re-sharing the information, will be prioritised to ensure that the content reaches identified target audiences.

Table 3: List of Tumor-LN-oC Twitter posts

#	Post topic	Date	Impressions	Engagement	Likes	Retweets	URL
1	Intro	11/01/2022	65	6	2	1	https://twitt
2	End-User questionnaire	13/01/2022	239	24	2	2	https://twitt
3	End-User questionnaire 2	17/01/2022	136	9	3	2	https://twitt
4	End-User questionnaire EURC	31/01/2022	122	4	1	1	https://twitt
5	International Day of Women a	11/02/2022	121	4	2	1	https://twitt
6	Partner ICCS	10/03/2022	51	2	0	0	https://twitt
7	Partner TU/e	16/03/2022	51	2	0	0	https://twitt
8	Partner BRFAA	18/03/2022	156	10	3	1	https://twitt
9	Partner AAU	22/03/2022	210	7	3	0	https://twitt
10	Partner Alpes	24/03/2022	111	3	2	1	https://twitt
11	SPIE Intro	28/03/2022	426	7	3	2	https://twitt
12	SPIE report	12/04/2022	99	8	3	0	https://twitt
13	World Health Day	19/04/2022	200	18	8	2	https://twitt
14	M12 Meeting	13/05/2022	517	24	9	5	https://twitt
15	IndTech 1	28/06/2022	88	9	5	0	https://twitt
16	IndTech 2	29/06/2022	199	11	3	2	https://twitt
17	ICCS + TU/e at Euroocs Grei	07/07/2022	174	8	2	0	https://twitt
18	TUW at ICPPP21	11/07/2022	23	2	1	0	https://twitt
19	RegMed invitation	15/07/2022	20	0	0	0	https://twitt
20	RegMed invitation 2	20/07/2022	25	1	0	0	https://twitt
21	Phos Print at Nanotexnology	25/07/2022	78	4	2	1	https://twitt
22	RegMed event	17/10/2022	61	15	6	2	https://twitt
23	M18 project + review meetinc	30/11/2022	146	13	5	2	https://twitt
24	PhosPrint selected as finalisz	12/12/2022	66	7	3	1	https://twitt
25	World Cancer Day	06/02/2023	44	3	2	1	https://twitt
26	World Health day (retweet frc	18/04/2023	3	0	0	0	https://twitt
27	**Status 18.04.2023**	**29**	**3431**	**201**	**70**	**27**	
Posts		Followers	Impressions	Engagement	Likes	Retweets	



Figure 14: Tumor-LN-oC Twitter page

Figure 15: Sample tweet

3.1.2. LinkedIn

Similar to Twitter, the Tumor-LN-oC LinkedIn account is used to share any news and updated, real-time information about the project. The account is maintained and updated by the dissemination manager.

As seen in Table 4, LinkedIn seems to have a better reach than Twitter, as consortium partners are more active on their own LinkedIn accounts (team members) and pages (partner organisations) and are actively engaging with and cross-sharing any news posts, which leads to more overall engagements. As of April 2023, Tumor-LN-oC project has 83 followers on LinkedIn and overall more than 6500 views of the 15 posts made, which is a satisfying result.

Table 4: Overview of Tumor-LN-oC LinkedIn posts

Nr.	Post topic	Date	Impressions	Unique impressions	Engage-ments	Reposts	Reactions	Comments	Clicks
1	End-User questionnaire	17/01/2022	229	71	22	3	7	0	12
2	End-User questionnaire EUROoCS	01/02/2022	434	241	38	3	13	0	22
3	2nd Milestone	28/03/2022	428	254	41	0	12	0	29
4	PhosPrint at SPIE	12/04/2022	148	44	8	3	1	0	4
5	World Health Day HaDEA	19/04/2022	120	52	10	0	4	0	6
6	M12 Meeting	20/05/2022	1782	1143	115	0	33	0	82
7	IndTech	01/07/2022	983	561	82	0	29	1	52
8	RedMed invite	20/07/2022	201	123	13	0	6	0	7
9	RedMed invite 2 (repost from AMIRES)	03/10/2022	58	34	5	0	4	0	1
10	RedMed invite 3 (repost from AMIRES)	11/10/2022	38	22	0	0	0	0	0
11	RegMed report	19/10/2022	700	470	54	1	23	1	29
12	M18 project and review meeting	30/11/2022	1116	841	48	4	24	0	20
13	PhosPrint selected as finalist at SPIE Sta	12/12/2022	54	38	7	0	6	0	7
14	PhosPrint 3rd place at SPIE Startup chal	08/02/2023	105	72	11	0	8	1	11
15	World Health Day HaDEA	12/04/2023	197	148	13	0	8	0	5
15	**Status 18.04.2023**	**83**	**6593**	**4114**	**467**	**14**	**178**	**3**	**244**
Posts		Followers	Impressions	Unique impressions	Engagement	Reposts	Reactions	Comments	Clicks



Figure 16:Tumor-LN-oC LinkedIn Page



Figure 17: Sample LinkedIn post

3.2. Graphics

Graphical content for the social media is prepared by the dissemination manager on Canva. Templates have been created in order to ensure coherent visual appearance.



Figure 18: Template for social media posts on Canva

3.3. Events and conferences

Attendance of events and conferences is one of the main ways in which Tumor-LN-oC partners engage with the scientific community beyond the project, make connections with other stakeholders, disseminate project results and gather relevant feedback. Relevant conferences and target audiences were identified in the Dissemination Strategy (D16.2) and continue to be relevant. This includes the :

Table 5: List of identified relevant conferences and events

Scientific conferences	Exhibitions / industry events
• MicroTas- International Conference on Miniaturized Systems for Chemistry and Life Sciences • SelectBio • SciX • EMRS meetings • International Conference on Advanced Vibrational Spectroscopy (ICAVS) • SPIE photonics • International Conference on Biosensing Technology • EOS conference in opto-fluidics, World Congress on Biosensors • Gordon Research Conferences • EMBO and EMBL conferences and workshops • EUROoCS annual conferences	• BioChip Berlin, • SELECTBIO Organ-on-a-Chip • SPIE Photonics West, • SPIE Photonics Europe, • European Materials Research Society (E-MRS) • CLEO Conference, • International Conference on Biomedical Imaging, • Signal Processing (ICBSP) • International Conference on Biomedical Engineering and Bioinformatics (ICBEB) • IPhEB Russia, • Rommedica, • Medicine and Health, • Swiss Medtech Expo, • Compamed

The consortium is very active in this respect and regularly participating in many events to present the project, disseminate its results, and network with other research, industry representatives and stakeholders (see Table 6).

The Dissemination manager is informing the consortium about any identified events, coordinating the Tumor-LN-oC presence, providing dissemination materials and encouraging follow-up with relevant contacts made. In addition, information about all dissemination activities including conference participation is regularly gathered during the internal reporting which takes place every 6 months. News about any significant conference participation is shared on the Tumor-LN-oC website and Social Media (see Figure 19 and Figure 20).

Figure 19: LinkedIn Post announcing Tumor-LN-oC participation at IndTech 2022 in Grenoble (June 2022)

Figure 20: Twitter Post announcing Tumor-LN-oC participation at Nanotexnology 2022

Table 6: Participation in events and conferences

Conference Name	Date	Location	Responsible Partner	Tumor-LN-oC participation	Link
		2021			
Webinar, organised by Medical school of the National % Kapodistrian University of Athens	08.10.2021	Online	ICCS: Ioanna Zergioti	Presentation	
Career in STEM	21.10.2021	University of Bern	ICCS: Ioanna Zergioti	Keynote lecture	
I3D21- Nanotexnology	07.-08.07.2021	Thessaloniki, Greece	ICCS: Ioanna Zergioti	Invited talk	https://www.nanotexnology.com/2021/
ASAC Meeting: "Next-Generation Analytical Chemists"	26.11.2021	Vienna/Online	TUW		https://anchem.univie.ac.at/vortraege-lehr-veranstaltungen/asac-2021/
30th Biocity Symposium / 14th Finnish Cancer Institute Symposium: Cancer – Breaking bad	19.-20.08.2021	Turku, Finland	AAU		https://www.bioimaging.fi/30th-biocity-symposium-register-now/
Joint Nordic Matrix Biology Meeting	03.-04.11.2021	Oulu, Finland	AAU		https://www.sidekudostutkijat.fi/arkisto/the-joint-nordic-matrix-biology-meeting
		2022			
SPIE Photonics West	22.-27.01.2022	San Francisco/ remote	TUW, ICCS		https://spie.org/conferences-and-exhibitions/photonics-west
Spring SciX	11.-14.04.2022	Liverpool	TUW		https://www.springscix.org/
SPIE Photonics Europe	03.-07.04.2022	Strasbourg	PhosPrint: Evina Elezoglou		https://spie.org/conferences-and-exhibitions/photonics-europe/programme
EMBO Workshop, Building Networks: Engineering in Vascular Biology	09.-11.05.2022	Barcelona	AAU: Cecilia Sahlgren	Presentation	https://www.embl.org/about/info/course-and-conference-office/events/evb22-01
Biochip Berlin, International Forum on BioChips and BioChip Solutions	10.-11.05.2022	Berlin	AMI: Kristin Aldag	Attendance, networking with exhibitors	https://biochip-berlin.de/
Biocity Symposium 2022, Solution is in Immunity	25-26.05.2022	Turku, Finland	AAU: Marjaana Parikainen	Poster presentation	https://biocityturku.fi/biocity-symposium/

ICPPP21 International Conference on Photoacoustic and Photothermal Phenomena	19.-24.06.2022	Bled, Slovenia	TUW: Elisabeth Holub	Poster presentation	https://indico.ung.si/event/5/
IndTech2022 – Industrial technologies conference	27.-29.06.2022	Grenoble	AMI: Kristin Aldag ICCS: Ioanna Zergioti	Distribution of leaflets	https://indtech2022.eu/
10th International Symposium and Scientific Meeting on Alagille Syndrome (ALGS meeting)	June 16-19th 2022	Cincinnati, Ohio, USA + online	AAU: Cecilia Sahlgren	Presentatio	https://www.eventbrite.com/e/10th-international-symposium-and-scientific-meeting-on-alagille-syndrome-registration-252581567267
European Organ-on-chip meeting 2022	04.-05.07.2022	Grenoble	ICCS: Marianneza Chatzipetrou, TU/e: Ye Wang	Poster presentation	https://euroocs.eu/annual-meeting/
Nanotexnology I3D22	05.-08.07.2022	Thessaloniki	PhosPrint: Evina Elezoglou	Presentation	https://www.nanotexnology.com/images/stories/food/I3D22_PROGRAM.pdf
The Next Gen Organ-on-Chip & Organoids workshop	23.-24.08.2022	Geneva	ICCS, ELV	Attendance, networking	https://www.csem.ch/page.aspx?pid=155967
"Cell la Vie"	21.-23.09.2022	Paris	ELV	Booth	https://sbcf.fr/en/event/cell-la-vie-2
Webinar Organized by Precisionary Instruments Inc	20.09.2022	Online	BRFAA, Katerina	Presentation	https://precisionary.com/support/product-support-menu/webinars/
SciX 2022	02.-07.10.2022	Covington, USA	TUW: Georg Ramer		https://scixconference.org/
Enhpathy MCSA-ITN	03.-07.10.2022	Santander, Spain	ELV: Julia Sepulveda		https://www.enhpathy.eu/wp-content/uploads/2022/09/Enhpathy-Event-V-Program.pdf
2nd Regenerative Medicine Workshop	12.10.2022	Prague	ICCS: Ioanna Zergioti AMI: Kristin Aldag	Presentation, round table	https://amires.eu/2nd-regenerative-medicine-workshop-october-12th-2022-prague-registration-is-open
Aurum Day	21.10.2022	Turku, Finland	AAU: KaiLan Lin	Poster presentation	
Nordic organoid/OoC zoom pitching event	27.10.2022	online	AAU: Kai-Lan Lin	Presentation	https://nordic-organ-on-a-chip.eu/
ÅAU Bioseminar	29.10.2022	Turku, Finland	AAU: Diosángeles Soto Véliz		
Cancer Biology GIDP Seminar Series	21.11.2022	Arizona, USA (online)	AAU: Cecilia Sahlgren		https://healthsciences.arizona.edu/connect/calendar/2022/cancer-biology-gidp-seminar-series-21

2023					
9th COST Action CardioRNA	22.-24.02.2023	Nicosia Cyprus	ICCS: Ioanna Zergioti	Oral Presentation	https://www.cost.eu/actions/CA17129/
EU FINANCE DAYS 2023	30.03.2023	Athens, Greece	PhosPrint: Ioanna Zergioti	Presentation	https://greece.representation.ec.europa.eu/news/i-eyropaiki-epitropi-di-organonei-tin-imerida-eu-finance-days-2023-tin-pempti-30-martioy-2023-stin-2023-03-23_el
MIT Global Startup Workshop (MIT GSW) 2023	30.-31.03.2023	Athens, Greece	PhosPrint; I.Zergioti, A. Klinakis; M. Pallidou; M. Dimadi	Presentation	https://gsw.mit.edu/2023/
Anakon 2023	11-14.04.2023	Vienna, Austria	TUW: Elisabeth Holub, Georg Ramer	Poster + oral presentation	https://www.anakon2023.at/

Table 7: Participation in events and conferences confirmed for 2023 and 2024

Conference Name	Date	Location	Responsible Partner	Tumor-LN-oC participation	Link
3rd Regenerative medicine workshop	01.06.2023	Prague, Czech Republic	PhosPrint; M. Pallidou, I. Theochari	Presentation	https://www.amires.eu/regmed2023-from-idea-to-patient-june-1st-prague/
Life at the periphery: mechanobiology of the cell surface	12.-15.06.2023	Heidelberg, Germany + virtual	AAU; Cecilia Sahlgren, KaiLan Lin	Attendance	https://www.embl.org/about/info/course-and-conference-office/events/ees23-05/
18th conference of the Hellenic Society of Pathological Anatomy	21.-24.06.2023	Volos, Greece	BRFAA	Poster	https://medicalcongress.gr/iatriko-synedrio/
32nd BioCity Symposium: Sculpting Tissues – cells, matrix and forces	24.-25.10.2023	Turku, Finland	AAU: Cecilia Sahlgren	Presentation	https://biocityturku.fi/biocity-symposium/
EMBL Conference, The new cardiobiology	20.-23.02.2024	Heidelberg, Germany	AAU: Cecilia Sahlgren	Presentation	https://www.embl.org/about/info/course-and-conference-office/events/ncb24-01/
Gordon Conference, Mechanisms of Notch Signaling in Health and Disease	14.-19.07.2024	Lewinston, ME, USA	AAU: Cecilia Sahlgren	Presentation	https://www.grc.org/notch-signaling-in-development-regeneration-and-disease-conference/2024/

3.4. Scientific Publications

As of M24, several technical and scientific publications related to Tumor-LN-oC have been published (see Table 8). At least one further publication regarding the cilia driven flow is currently under preparation by TU/e.

Table 8: Overview of Tumor-LN-oC scientific publications

Scientific Publication	Title	Author	DOI	Publication Date
Biosensors	Bioprinting on Organ-on-Chip: Development and Applications	ICCS, PhosPrint: Maria Anna Chliara, Evina Elezoglou, Ioanna Zergioti	10.3390/bios12121135	06.12.2022
Smart Medicine	Organ-on-a-chip technologies for biomedical research and drug development: A focus on the vasculature	AAU: Diosangeles Soto Veliz, Kai-Lan Lin, Cecilia Sahlgren	10.1002/SMMD.20220030	24.02.2023
Advanced Chemical Microscopy for Life Science and Translational Medicine 2023 (SPIE)	Image processing as basis for chemometrics in photothermal atomic force microscopy infrared imaging	TUW: Georg Ramer, A. Catarina V. D. dos Santos, Yide Zhang, Ufuk Yilmaz, Bernhard Lendl	10.1117/12.2651424	17.03.2023

During project meetings, several team members have pointed out that in biomedical research, it takes a while until publishable results are achieved. In addition, intellectual property-considerations are not yet finalised and publication of some results might be postponed until this is clarified.

In line with the DoA and dissemination strategy, open-access publications is chosen wherever possible. All open-access articles will be linked on the Tumor-LN-oC website as well as published to the community on Zenodo: https://zenodo.org/communities/tumor-ln-oc/. Zenodo was created within the OpenAIRE project, commissioned by the EC to support open access and open data movements in Europe by providing a catch-all repository for EC funded research and hosted securely by CERN.



Figure 21: Tumor-LN-oC community on Zenodo

According to article 8.4.2 of the Consortium Agreement ("Dissemination of Results"), during the Project and for a period of 1 year after the end of the Project, the dissemination of any material and/or own results by one or several partners including, but not restricted to, publications and presentations, shall be governed by the procedure of Article 29.1 of the Grant Agreement subject to the provisions outlined in Figure 22. In practice, this means that all intended publications are shared with other partners prior to submission who have a chance to voice any objections.



Figure 22: Procedure outlined in article 8.4.2 of the consortium agreement

3.5. Clustering and engagement with other projects

As encouraged by the project officer, contact was sought with Tumor-LN-oC "sister projects" which were funded under the same call for proposals, H2020-NMBP-TR-IND-2020-twostage. Successful cooperation was established with two out the three projects:

Table 9: Clustering with other EU project

Project Acronym + Website	Coordinator	Status of cooperation
Gutvibrations https://gutvibrations.org/	**Dasja Pajkrt** Amsterdam UMC	Initial meeting 23.06.2022 Cooperation established
EMAPS-Cardio https://emaps-cardio.eu/	**Christian Bergaud** Laboratory for Analysis and Architecture of Systems	Initial Meeting 16.06.2022 Cooperation established
Flamingo https://flamingo-joc.eu/	**Prof. Annalisa Chiocchetti** Università del Piemonte Orientale	Several emails sent in order to set up an initial meeting, unfortunately no reply yet, follow-up request will be sent

Cooperation mainly consist in progress updates and sharing of challenges, sharing of news or events on request, as well as potential future joint organisation and/or participation in events. The project coordinator and dissemination manager will continue to be in touch with these projects and proactively identify and further EU-funded projects or related initiatives

4. Review of project dissemination strategy

The project dissemination strategy was outlined in D16.1. No significant update is considered necessary at this time. Considerations regarding target audience still apply. Upon conclusion of T17.1, the implementation and coordination of dissemination activities will continue in task T18.1.

5. Conclusions

This Deliverable reports on the dissemination activities carried out by Tumor-LN-oC partners during the project duration and in particular between M6 (establishment of dissemination strategy) and M24.

The dissemination manager role was established and awarded to Kristin Aldag from AMIRES. A dedicated project website and selected social medial channels inform about the project and are regularly updated with any news. Three scientific publications have been published and more are under preparation. Tumor-LN-oC promotional materials have been created to raise awareness and inform the general public and identified target audiences about the Tumor-LN-oC project and its development. These materials will be extensively used by Tumor-LN-oC partners during conferences, industry fairs, future workshops, and other occasions. Partners have presented the project at over 20 events and conferences. Clustering with related project was initiated. All dissemination activities are being tracked and reported by the dissemination manager.

6. Degree of Progress

This deliverable is 100% complete and concludes the task 17.1.

7. Dissemination level

This Deliverable D17.1 is public and will be made available to download on the project's website.